Patients with Laron syndrome are protected from development of cancer even if treated with IGF-I

Laron Zvi
Rachel Steuerman
Shevah Orit
Kauli Rivka

Endocrinology & Diabetes Research Unit, Schneider Children's Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel

Address for correspondence:
Laron Zvi
Endocrinology & Diabetes Research Unit
Schneider Children's Medical Center
Sackler School of Medicine
Tel-Aviv University, Israel
E-mail: laronz@clalit.org.il

Summary
In accordance with the link between increased GH and IGF-I secretion and cancer, we found that homozygous patients with Laron syndrome (severe GH insensitivity) and low to undetectable serum IGF-I are protected from developing cancer even if treated with IGF-I to enhance linear growth.

KEY WORDS: Laron syndrome; GH receptor; IGF-I and cancer; GH insensitivity; cancer.

Introduction
Cancer cells are characterized by their capacity for self-sufficient proliferation, refractoriness to growth inhibitory signals, resistance to apoptosis and capacity to recruit angiogenesis (1). The causes of cancer include genetic predisposition, gene-environment interactions and infections agents. Among the risk factors are hormones including pituitary growth hormone (GH) and insulin like growth factor I (IGF-I) (2-4). In 1966 we described a new disease resembling congenital isolated GH deficiency (c1GHD) (5) but which surprisingly was found to be characterized by high serum levels of GH and low to undetectable levels of IGF-I (6). The patients originated from the Middle East and most belonged to consanguineous families (7). Subsequently more patients were diagnosed in various parts of the world (5), and the disease was coined by William Daughaday Laron type dwarfism, and changed subsequently to Laron syndrome (LS, OMIM#262500). In 1983 we showed that liver membranes of LS patients could not bind 125I-hGH explaining the etiology of this disease as insensitivity (resistance) to GH (8), subsequently we and others demonstrated that the resistance to GH was due to deletions (9) or mutations in the hGH receptor (5, 10).

Aim of Study
Having a population with an inability to generate IGF-I we considered it to be the right model to test, the relationship between IGF-I deficiency and cancer. We hypothesized that if indeed GH/IGF-I promotes malignancy: patients with congenital IGF-I deficiency as exemplified by Laron syndrome should be cancer free.

Subjects and Methods
To test this hypothesis we analyzed the medical charts of our 68 LS patients, sent a questionnaire to medical clinics known to follow patients with LS and screened the medical literature for published patients (11-13). We were able to collect data on 234 patients with LS, adding recently 4 new patients to those included in the report by Steuerman et al. (14). Dr Guevara-Aguirre who follows 99 patients in Ecuador expressed the wish to analyze their patients separately (personal communication).

Statistics
The collected data were analyzed using the BMDP statistical software (14). One-way and two-way ANOVA were used to analyzed continuous variables (age) and as for discrete variables (diagnosis/type of malignancy). $X^2$ test and Fisher's exact test were used. A P value <0.05 was considered statistically significant.

Results
The study was performed in two stages: the first part performed during the years 2004-2006, led to the announce-
Patients with Laron syndrome are protected from development of cancer even if treated with IGF-I

ment of the preliminary and exciting results in 2005 at a cancer meeting in Taormina (15) namely that none of the LS patients had developed cancer their age ranging from 3-78 years with a mean age of 32.3 years in our cohort and 16 years in the US and European one. These findings in 169 patients with Laron syndrome and 250 relatives were published in 2007 (16). We continued to collect data to ascertain these findings and published the second stage early in the year 2011 (14). The study was updated until August 2013. Table 1, which also includes the findings of the Ecuadorian groups (17).

It is evident that none of the homozygous LS patients, many of them adults, even old, had developed any malignancy whereas their heterozygote 1st degree relatives have.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Malignancies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  N   %</td>
</tr>
<tr>
<td>Laron syndrome</td>
<td>234 0    0</td>
</tr>
<tr>
<td>1st degree relatives</td>
<td>218 17   8.3</td>
</tr>
</tbody>
</table>

**Discussion**

Our findings that homozygous patients with Laron syndrome are protected from developing cancer have been confirmed by Guevara-Aguirre et al. (17) who surveyed 99 patients with LS in Ecuador. One of their LS patients who developed ovarian carcinoma was a double heterozygote.

The mechanism which protects the patients with Laron syndrome is so far undetermined. Their 1st degree heterozygote family members (parents and siblings) who are not protected from cancer do not resemble phenotypically LS patients (6, 7). The cause must be related to the fact that the heterozygote subjects produce active growth hormone and IGF-I. The conclusion is that only complete congenital absence of IGF-I induces a cancer protective mechanism.

We (18) and probably others (17) are taking on the challenge to solve the riddle which should lead not only to a better understanding of the link between IGF-I and cancer but hopefully to improved and novel treatment.

**References**

ciency is associated with a major reduction in pro-ag-
ing signaling, cancer and diabetes in humans. Sci
Transl Med 2011; 3(70):doi:10.1126/scitransl-
med.3001845.

18. Lapkina L, Laron Z, Werner H, Genome-wide analy-
sis of cancer protection pathways in Laron Syndrome
patients. Abstr# P01-22. Growth Hormone & IGF Re-